{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T01:46:13Z","timestamp":1785721573056,"version":"3.56.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009253","name":"EASL International Liver Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejim.2026.106883","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:56:33Z","timestamp":1776311793000},"page":"106883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["From unmet needs to new possibilities: PPAR-targeted therapies in the journey of people living with Primary Biliary Cholangitis"],"prefix":"10.1016","volume":"150","author":[{"given":"Antonella","family":"Ruiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Meschisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Plebani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buzias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0561-7902","authenticated-orcid":false,"given":"Ana","family":"Lleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Ronca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejim.2026.106883_bib0001","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106883_bib0002","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"issue":"10457","key":"10.1016\/j.ejim.2026.106883_bib0003","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","article-title":"Primary biliary cholangitis","volume":"404","author":"Tanaka","year":"2024","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.ejim.2026.106883_bib0004","doi-asserted-by":"crossref","first-page":"771","DOI":"10.5009\/gnl16365","article-title":"Extrahepatic manifestations of primary biliary cholangitis","volume":"11","author":"Chalifoux","year":"2017","journal-title":"Gut Liver"},{"issue":"2","key":"10.1016\/j.ejim.2026.106883_bib0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.51.2.265","article-title":"Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis","volume":"51","author":"Longo","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2026.106883_bib0006","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9151525","article-title":"The epidemiology of primary biliary cholangitis in European countries: a systematic review and meta-analysis","volume":"2021","author":"Gazda","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106883_bib0007","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47890-2","article-title":"Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort","volume":"9","author":"Marschall","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejim.2026.106883_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/srep25906","article-title":"Evolving trends in female to male incidence and male mortality of primary biliary cholangitis","volume":"6","author":"Lleo","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ejim.2026.106883_bib0009","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.ejim.2026.106883_bib0010","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.ejim.2026.106883_bib0011","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000440829","article-title":"Pathogenesis and management of pruritus in PBC and PSC","volume":"33","author":"Kremer","year":"2015","journal-title":"Dig Dis"},{"issue":"3","key":"10.1016\/j.ejim.2026.106883_bib0012","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejim.2026.106883_bib0013","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/hep.31810","article-title":"Accuracy of transient elastography in assessing fibrosis at diagnosis in na\u00efve patients with primary biliary cholangitis: a dual cut-off approach","volume":"74","author":"Cristoferi","year":"2021","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.ejim.2026.106883_bib0015","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ejim.2026.106883_bib0016","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouill\u00e8res","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejim.2026.106883_bib0017","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.ejim.2026.106883_bib0018","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.ejim.2026.106883_bib0019","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejim.2026.106883_bib0020","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ejim.2026.106883_bib0021","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ejim.2026.106883_bib0022","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ejim.2026.106883_bib0023","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.ejim.2026.106883_bib0024","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.ejim.2026.106883_bib0025","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.ejim.2026.106883_bib0026","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should Be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.ejim.2026.106883_bib0027","article-title":"Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis","volume":"6","author":"Roberts","year":"2024","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106883_bib0028","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","article-title":"Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: to what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?","volume":"79","author":"Corpechot","year":"2024","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejim.2026.106883_bib0029","doi-asserted-by":"crossref","first-page":"390","DOI":"10.14309\/ajg.0000000000003029","article-title":"COBALT: a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls","volume":"120","author":"Kowdley","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.ejim.2026.106883_bib0030","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatol Res Off J Jpn Soc Hepatol"},{"issue":"5","key":"10.1016\/j.ejim.2026.106883_bib0031","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"issue":"23","key":"10.1016\/j.ejim.2026.106883_bib0032","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejim.2026.106883_bib0033","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejim.2026.106883_bib0034","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of Seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.106883_bib0036","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study","volume":"58","author":"Mells","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejim.2026.106883_bib0037","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2010.05.026","article-title":"The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up","volume":"53","author":"Jones","year":"2010","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.ejim.2026.106883_bib0038","article-title":"A home-based exercise programme attenuates fatigue in primary biliary cholangitis: results from the EXCITED clinical trial","volume":"6","author":"Freer","year":"2024","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.ejim.2026.106883_bib0039","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s41687-024-00722-y","article-title":"Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial","volume":"8","author":"von Maltzahn","year":"2024","journal-title":"J Patient-Rep Outcomes"},{"key":"10.1016\/j.ejim.2026.106883_bib0040","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3389\/fphys.2018.01530","article-title":"Morning bright light treatment for sleep-wake disturbances in primary biliary cholangitis: a pilot study","volume":"9","author":"Turco","year":"2018","journal-title":"Front Physiol"},{"issue":"3","key":"10.1016\/j.ejim.2026.106883_bib0041","doi-asserted-by":"crossref","first-page":"273","DOI":"10.15403\/jgld.2014.1121.273.icz","article-title":"Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study","volume":"27","author":"Wunsch","year":"2018","journal-title":"J Gastrointest Liver Dis JGLD"},{"issue":"3","key":"10.1016\/j.ejim.2026.106883_bib0042","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/jca.21573","article-title":"Plasma exchange for the management of refractory pruritus of cholestasis: a report of three cases and review of literature","volume":"33","author":"Chkheidze","year":"2018","journal-title":"J Clin Apheresis"},{"issue":"1","key":"10.1016\/j.ejim.2026.106883_bib0043","first-page":"112","article-title":"Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis","volume":"42","author":"Kremer","year":"2022","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"9","key":"10.1016\/j.ejim.2026.106883_bib0044","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70276","article-title":"Assessment of PBC pruritus from the ITCH-E study: quality of life, productivity, and treatment experiences","volume":"45","author":"Levy","year":"2025","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.ejim.2026.106883_bib0045","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.05.009","article-title":"Lysophosphatidic acid is a potential mediator of cholestatic pruritus","volume":"139","author":"Kremer","year":"2010","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.ejim.2026.106883_bib0046","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2165\/00003495-200868150-00006","article-title":"Pathogenesis and treatment of pruritus in cholestasis","volume":"68","author":"Kremer","year":"2008","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ejim.2026.106883_bib0047","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2026.106883_bib0048","article-title":"Long-term efficacy and safety of selective PPAR\u03b4 agonist seladelpar in primary biliary cholangitis: ASSURE interim study results","author":"Levy","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106883_bib0049","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2468-1253(25)00192-X","article-title":"Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Hirschfield","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.ejim.2026.106883_bib0050","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep4.1305","article-title":"A randomized, controlled, phase 2 study of Maralixibat in the treatment of itching associated with primary biliary cholangitis","volume":"3","author":"Mayo","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ejim.2026.106883_bib0051","article-title":"Volixibat leads to improvements in fatigue and sleep for adults with PBC: data from VANTAGE","volume":"21","year":"2025","journal-title":"Gastroenterol Hepatol"},{"issue":"2\u20133","key":"10.1016\/j.ejim.2026.106883_bib0035","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12016-014-8427-x","article-title":"Extrahepatic autoimmune conditions associated with primary biliary cirrhosis","volume":"48","author":"Floreani","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.ejim.2026.106883_bib0053","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.15214","article-title":"Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence and significance for clinical presentation and disease outcome","volume":"36","author":"Efe","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.ejim.2026.106883_bib0054","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/2042018816641351","article-title":"Osteoporosis in liver disease: pathogenesis and management","volume":"7","author":"Handzlik-Orlik","year":"2016","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ejim.2026.106883_bib0055","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/hep.26466","article-title":"Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis","volume":"58","author":"Gua\u00f1abens","year":"2013","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.ejim.2026.106883_bib0056","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.3390\/jcm13092714","article-title":"Cholangitis and fatty liver disease: the close underexplored relationship: a narrative review","volume":"13","author":"Greco","year":"2024","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.ejim.2026.106883_bib0057","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4254\/wjh.v3.i4.93","article-title":"Asymptomatic primary biliary cirrhosis is not associated with increased frequency of cardiovascular disease","volume":"3","author":"Doycheva","year":"2011","journal-title":"World J Hepatol"},{"issue":"6","key":"10.1016\/j.ejim.2026.106883_bib0058","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.aohep.2019.07.006","article-title":"Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis","volume":"18","author":"Loaeza-del Castillo","year":"2019","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.ejim.2026.106883_bib0059","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1142177","article-title":"Prevalence and prognostic significance of main metabolic risk factors in primary biliary cholangitis: a retrospective cohort study of 789 patients","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Endocrinol"},{"issue":"11","key":"10.1016\/j.ejim.2026.106883_bib0060","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/hepr.12452","article-title":"Coronary artery disease in primary biliary cirrhosis: a systematic review and meta-analysis of observational studies","volume":"45","author":"Ungprasert","year":"2015","journal-title":"Hepatol Res Off J Jpn Soc Hepatol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526001883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526001883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T01:14:48Z","timestamp":1785719688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526001883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":58,"alternative-id":["S0953620526001883"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106883","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From unmet needs to new possibilities: PPAR-targeted therapies in the journey of people living with Primary Biliary Cholangitis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106883"}}